Swedish Orphan Biovitrum AB (publ) drugs
4 results
Gamifant (emapalumab-lzsg)
(emapalumab-lzsg)Swedish Orphan Biovitrum AB (publ)
Usage: GAMIFANT is indicated for the treatment of adults and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent, or progressive disease, or who are intolerant to conventional HLH therapy.
Kineret (anakinra)
(anakinra)Swedish Orphan Biovitrum AB (publ)
Usage: KINERET is indicated for treating moderately to severely active rheumatoid arthritis in adults who have not responded to DMARDs, as well as for Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). It can be used alone or with non-TNF blocking DMARDs.
Orfadin (nitisinone)
(Nitisinone)SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Usage: ORFADIN® is indicated for the treatment of hereditary tyrosinemia type 1 (HT-1) in both adult and pediatric patients, used alongside a diet that restricts tyrosine and phenylalanine.
Synagis (palivizumab)
(palivizumab)Swedish Orphan Biovitrum AB (publ)
Usage: Synagis is indicated for preventing serious lower respiratory tract disease caused by RSV in pediatric patients with a history of premature birth, bronchopulmonary dysplasia requiring treatment, or hemodynamically significant congenital heart disease, all under specific age limits at the start of RSV season.